Form 4: Athira Pharma Director Kelly A. Romano Acquires Stock Options

Director Kelly A. Romano acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024, according to a Form 4 filing.

Summary

• On May 24, 2024, Kelly A. Romano, a director of Athira Pharma, Inc., acquired 20,900 stock options.
• The exercise price of these options is $2.64.
• The options vest on the earlier of May 24, 2025, or the day before the next annual meeting of the Issuer's stockholders after May 24, 2024.
• The options expire on May 23, 2034.
• Following the transaction, Romano directly owns 20,900 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally viewed as a positive sign, but without additional context, the impact is limited.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates